Calculus of frustration

As BioCentury's cover story this week reports, some U.S. companies are finding good reasons for exporting clinical development activities to Europe, and are keeping an eye on the prospects for accelerated market approval there, compared to the U.S. Here are four good reminders why the grass may look greener elsewhere:

• Telios Pharmaceuticals submitted its PLA and waited for the FDA to file it, only to find out nine months later that the agency had a few questions it wanted answered. The delay will set back TLIO's timetable by a year or two. ...